MARKET WIREStockInvest.us • 7h ago
Kazia Therapeutics Stock Price Forecast. Should You Buy KZIA?StockInvest.us report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
Why KZIA Stock dropped -2.52% Today — RQD Quant Desk Flash
$8.50 -2.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.45
Kazia Therapeutics Limited (KZIA) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $135.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KZIA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KZIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Kazia Therapeutics Limited (NASDAQ: KZIA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $8.50 (-2.52% 1D, market cap $135.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KZIA ranks #170 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KZIA compare to OGI and SPRB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KZIA carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OGI (Organigram Global Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, KZIA leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KZIA?
▼
For Kazia Therapeutics Limited (KZIA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #170 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.45 (-0.64%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+1.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KZIA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (61/100 Composite)
🔍 WHY KZIA SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)
FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 46 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$8.81-10.9% Next Q
69
Q2 (-2Q)Grade B-$7.85+0.3% Next Q
66
Q3 (-1Q)Grade C+$7.87+8% Next Q
64
CurrentGrade C-$8.50+0.5% Hist 90D α
61
Trajectory: B- (69) → C- (61)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the KZIA Bull Thesis Could Fail
Even with a 61/100 (C-) score, KZIA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.13) or 200D SMA ($10.55) invalidates the momentum regime and cuts Target Base ($8.61) toward Bear Floor ($6.72).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KZIA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KZIA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KZIA Stock dropped -2.52% Today — RQD Quant Desk Flash
Kazia Therapeutics Limited (KZIA) dropped -2.52% to $8.50, trading at 29% of its 52-week range ($4.86 – $17.4). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 29% of its 52-week range ($4.86 – $17.4) with RSI-14 at 46 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $3.8M annual free cash flow.
Live KZIA Headlines & Catalysts
CATALYSTTradingView • 10h ago
Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% UpsideTradingView report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 13h ago
Kazia stock gains as Guggenheim starts at Buy (KZIA:NASDAQ)Seeking Alpha report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 16h ago
5,713,449,734 Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 28-OCT-2026.www.marketscreener.com report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 19h ago
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayBenzinga report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 22h ago
A live webcast will carry Kazia executives’ Nov. 9 conference chat.Stock Titan report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Kazia Therapeutics Limited Stock Price Today | KZIA Live Chart & NewsTraders Union report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Kazia Therapeutics Limited Stock Price Prediction: Today, Tomorrow, Next Week (KZIA)Traders Union report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 10h ago
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer SymposiumKazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome tre
MARKET WIREBenzinga • 13h ago
Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer SymposiumPresentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming ActivitySYDNEY, Nov. 2, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (KZIA Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KZIA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.80%📐 HORIZONTAL RANGE
2026-11-02O $8.63H $8.75L $8.35C $8.50VOL 19.4K
RES: $18.39SUP: $5.47SMA50: $10.13SMA200: $10.55
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KZIA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KZIA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KZIA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KZIA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KZIA)
Health Care Rank #170 of 1016
⚔️ OGI vs KZIA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KZIA vs. OGI, SPRB, CATX, NBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Kazia Therapeutics Limited (KZIA) ranks #170 by composite RQD confidence (61/100, grade C-) and #622 by equity capitalization ($135.6M). Within this direct 5-issuer industry benchmark cohort, KZIA leads on earnings valuation at N/A trailing P/E, while SPRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with KZIA at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KZIA
ACTIVE
Kazia Therapeutics Limited | C- | 61/100 | — | — | — | -2.52% | $135.6M | Benchmark Subject |
| OGI Organigram Global Inc. | C | 62/100 | — | — | — | -2.85% | $135.4M | /ogi-vs-kzia → |
| SPRB Spruce Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -0.92% | $134.6M | /sprb-vs-kzia → |
| CATX Perspective Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -1.71% | $133.6M | /catx-vs-kzia → |
| NBP NovaBridge Biosciences | D- | 38/100 | — | — | -35.0% | -1.24% | $139.6M | /nbp-vs-kzia → |
2. KZIA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTKazia Therapeutics Limited (KZIA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $135.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. KZIA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KZIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Kazia Therapeutics Limited (NASDAQ: KZIA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $8.50 (-2.52% 1D, market cap $135.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KZIA ranks #170 in composite RQD confidence.
How does KZIA compare to OGI and SPRB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KZIA carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OGI (Organigram Global Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, KZIA leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KZIA?
For Kazia Therapeutics Limited (KZIA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #170 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KZIA trading relative to its 50-day, 200-day, and 52-week technical levels?
KZIA last traded at $8.50 (-2.52% on volume of 230,442 shares), positioning the stock -16.09% below its 50-day simple moving average ($10.13) and -19.43% below its 200-day simple moving average ($10.55). Across its 52-week range of $4.86 to $17.40, KZIA sits at the 29.0% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.44 to $9.56).
KZIA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KZIA stock moving today?
Why KZIA Stock dropped -2.52% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 61/100 (C-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
KZIA — Kazia Therapeutics Limited: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:18:04Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 61, graded C- and labeled "Roarable Hold — Cautious Neutral," per the Roarable RQD rating. Across its five pillars:
- Fundamental Cash Engine (12 / 20): Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the cash-generation pillar is the weakest of the fundamental inputs in the rating: the source data shows no return on invested capital and no free-cash-flow yield to anchor valuation.
- Whale 13F Flow (12 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying 13F and options detail is not itemized in the source data, so the score can be read as moderate institutional interest without the specifics behind it.
- Insider Conviction (9 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar score, suggesting insider and congressional activity provides limited conviction support in this rating.
- Macro Regime Fit (15 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity. A beta of 1.0 implies market-matching sensitivity to broad moves, which is a neutral macro posture rather than a defensive or aggressive one.
- Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. These are the strongest pillar inputs and indicate a balance sheet that is more stable than the cash-generation pillar alone would suggest.
Taken together, the rating frames KZIA as a stock where balance-sheet forensics are the most supportive element, while cash generation and insider conviction are the weakest. Valuation tradeoffs cannot be assessed directly because P/E, EV/EBITDA, and EPS are not available in source data, so upside claims must be weighed against the absence of earnings-based valuation anchors.
Business
Kazia Therapeutics Limited (KZIA) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the company profile. Its market capitalization is $0.1B per the company profile. Products sold, customer base, and revenue model are not available in source data.
Recent Catalysts & News Wire Analysis
- Green catalysts: A TradingView report (per the news feed) carries the headline "Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% Upside" (flagged GREEN, CATALYST). A Benzinga report flags a bullish analyst initiation (GREEN, CATALYST). A Seeking Alpha report notes Guggenheim starting coverage at Buy (GREEN, CATALYST).
- Yellow market-wire items: A StockInvest.us forecast piece (YELLOW, MARKET WIRE) and a MarketScreener notice that 5,713,449,734 Ordinary Shares are subject to a Lock-Up Agreement ending 28-OCT-2026 (YELLOW, MARKET WIRE).
- Red risk-watch item: A Stock Titan report that a live webcast will carry Kazia executives' Nov. 9 conference chat (RED, RISK WATCH). The feed labels this as risk-watch, but the headline itself does not state the nature of the risk.
- Proprietary signals: None. The Butterfly Supply-Chain Graph lists no butterfly links and no proprietary signals.
The lock-up expiry on 28-OCT-2026 is noteworthy relative to the data date of 2026-11-02, as it falls before the as-of date.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain is "NONE" and there are no butterfly links. Upstream and downstream dependencies, sector correlations beyond the Health Care classification, and second-order bottlenecks are not available in source data. The one ripple-relevant item is the large lock-up share count noted in the news feed; the scale of that overhang relative to the $0.1B market capitalization is a second-order consideration for float and supply of shares.
Open Questions
- What are the reported revenue, earnings, and cash-flow figures behind the 0% margins and ROIC cited in the RQD rating?
- Which specific 13F holders and options positions underlie the 12 / 20 whale-flow pillar score?
- What is the composition and identity of the insider Form 4 and Congressional trades driving the 9 / 20 insider-conviction score?
- What is the analyst consensus rating and price-target distribution behind the headline targets in the news feed?
- What is the nature of the risk flagged in the Stock Titan item, and how does the 5,713,449,734-share lock-up expiry affect float?
KZIA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Kazia Therapeutics Limited (KZIA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 7h ago
Kazia Therapeutics Stock Price Forecast. Should You Buy KZIA? StockInvest.us report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 10h ago
Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% Upside TradingView report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 13h ago
Kazia stock gains as Guggenheim starts at Buy (KZIA:NASDAQ) Seeking Alpha report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 16h ago
5,713,449,734 Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 28-OCT-2026. www.marketscreener.com report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 19h ago
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Benzinga report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 22h ago
A live webcast will carry Kazia executives’ Nov. 9 conference chat. Stock Titan report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Kazia Therapeutics Limited Stock Price Today | KZIA Live Chart & News Traders Union report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Kazia Therapeutics Limited Stock Price Prediction: Today, Tomorrow, Next Week (KZIA) Traders Union report covering Kazia Therapeutics Limited (KZIA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
KZIA Bull vs. Bear Conversation Board — What's Your Call at $8.50?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KZIA 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $9.42 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is KZIA (C- • RQD 61/100) a Buy at $8.72?
Welcome to the KZIA (Kazia Therapeutics Limited) Roar Pit. Current RQD Composite is 61/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $7.32 (-16.1%)
Spot @ $8.72 Pump the brakes on KZIA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on KZIA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kazia Therapeutics Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $10.81 (+24.0%)
Spot @ $8.72 KZIA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on KZIA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.72 (52-wk range $7.22 - $9.14), any beat on forward guidance forces shorts and underweight funds to chase.